| 000 | 01148 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250518064113.0 | ||
| 264 | 0 | _c20200302 | |
| 008 | 202003s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdz404 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBrandão, M | |
| 245 | 0 | 0 |
_aPatient-reported outcomes and genomic signatures: tools to tailor adjuvant endocrine treatment? _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _c11 2019 |
||
| 300 |
_a1677-1681 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 | _aAntineoplastic Agents, Hormonal |
| 650 | 0 | 4 | _aBreast Neoplasms |
| 650 | 0 | 4 | _aChemotherapy, Adjuvant |
| 650 | 0 | 4 | _aGenomics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aPatient Reported Outcome Measures |
| 650 | 0 | 4 | _aTamoxifen |
| 700 | 1 | _aCoens, C | |
| 700 | 1 | _aIgnatiadis, M | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 30 _gno. 11 _gp. 1677-1681 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdz404 _zAvailable from publisher's website |
| 999 |
_c30202449 _d30202449 |
||